Add BrightSurf on Google Email

Taming overactive immune systems with antibodies: hope for autoimmune diseases

A multi-institutional team has discovered a novel immune regulatory mechanism mediated by antibodies that selectively shut down overactive immune responses. The 'immune-induced TCR-like antibody' (iTab) can reduce disease severity and delay its onset in a mouse model of autoimmune disease.

SourceImmunology Frontier Research Center (IFReC) - The University of Osaka·JournalNature Communications·TypeExperimental study·DateApr 22, 2026

New bioactive compound for difficult-to-treat allergies

Researchers have discovered a promising bioactive compound that can effectively reduce symptoms of conditions like asthma and migraine by blocking a receptor on certain defense cells. The compound is effective in eliminating life-threatening allergic reactions in mice and has shown promise for treating inflammatory conditions.

SourceUniversity of Bonn·JournalSignal Transduction and Targeted Therapy·TypeExperimental study·DateApr 24, 2025

Peptide synthesized at University of São Paulo acts as molecular shield to prevent SARS-CoV-2 from infecting cells

Researchers at the University of São Paulo developed a synthetic peptide that mimics the ACE2 receptor, blocking SARS-CoV-2 invasion and reducing inflammation in human lung cells and mice. The peptide could be customized for every variant, offering a fast-acting molecular shield against the virus.

Using a molecular scissors to improve CAR-T cell therapy

CAR-T cell therapy, a regenerative immunotherapy, has shown promise in treating blood cancers but struggles with T-cell exhaustion. Researchers have discovered that overproduction of the IL-4 protein causes this exhaustion and used CRISPR gene-editing technology to remove it, improving CAR-T cell therapy outcomes.

SourceMayo Clinic·JournalNature Communications·DateSep 12, 2024

Improved chemokine homing enhances CAR T–cell therapy for osteosarcoma

Scientists at St. Jude Children's Research Hospital identified two chemokines, CXCL8 and CXCL16, expressed by osteosarcoma that improved CAR T-cell homing. Modified cells expressing these chemokine receptors showed enhanced infiltration into tumors, leading to prolonged survival in a model of metastatic disease.

SourceSt. Jude Children's Research Hospital·JournalClinical Cancer Research·TypeExperimental study·DateAug 5, 2024

Mini lungs make major COVID-19 discoveries possible

Researchers have discovered that SARS-CoV-2 can infect more types of lung cells than previously thought, including those without known viral receptors. The study also found that the lung can independently muster an inflammatory antiviral response without immune system help when exposed to the virus.

SourceSanford Burnham Prebys·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateJul 23, 2024

GZ17-6.02 kills PDX isolates of uveal melanoma

Researchers found that GZ17-6.02 killed uveal melanoma cells by enhancing autophagy, inactivating key proteins, and reducing growth factors. The compound also interacted with doxorubicin and ERBB inhibitors to enhance tumor cell killing, suggesting potential as a single agent or combination therapy.

SourceImpact Journals LLC·JournalOncotarget·TypeExperimental study·DateMay 22, 2024

NTRK gene fusion in papillary thyroid cancer: A clinicogenomic biobank and record linkage study from Finland

Researchers identified NTRK gene fusion in 1.5% of Finnish papillary thyroid cancer patients, with notable co-occurring genetic alterations and favorable treatment outcomes. The study highlights the potential for biobank samples linked to electronic health records to describe patient characteristics and outcomes.

SourceImpact Journals LLC·JournalOncotarget·TypeObservational study·DateFeb 19, 2024

Plant receptors that control immunity and development share a common origin

Researchers have discovered that plant immune receptors and growth-related proteins share a common evolutionary ancestry, allowing for the creation of hybrid receptors with enhanced functionality. This breakthrough could lead to the development of disease-resistant crops by isolating and engineering immune receptors from various plants.

SourceRIKEN·JournalNature Communications·TypeExperimental study·DateFeb 1, 2024

How immune cells recognize their enemies

Researchers discovered how Vγ9Vδ2 T cells recognize pathogens and cancer cells by their altered cell metabolism. The study found that phosphoantigens bind to special molecules inside the cell, triggering a signal to kill. This finding can improve the clinical use of Vγ9Vδ2 T cells in tumor treatment.

SourceUniversity of Würzburg·JournalNature Communications·TypeExperimental study·DateDec 8, 2023

Study identifies a key protein for healthy aging

Researchers have discovered that a specific immune receptor, CD300f, plays a crucial role in determining the onset of age-related pathologies, including cognitive decline and premature aging. The study found that mice lacking this receptor developed accelerated aging and related disorders, particularly in females.

SourceUniversity of Barcelona·JournalCell Reports·TypeExperimental study·DateNov 28, 2023

Synthetic peptide could reduce vascular problems associated with COVID-ARDS

Researchers have developed a synthetic peptide that could help reduce vascular problems associated with acute respiratory distress syndrome in COVID-19. The peptide, called TIP, works by binding to a subunit of the epithelial sodium channel, which helps maintain barrier function and prevent damage from viral proteins.

SourceMedical College of Georgia at Augusta University·JournalFrontiers in Immunology·DateOct 3, 2023

Immune cells shape their own path

Researchers at ISTA discovered that immune cells actively shape their environment by consuming chemokine signals, allowing them to generate their own guidance cues. This dynamic regulation enables collective migration of immune cells and has significant implications for enhancing immune response coordination.

SourceInstitute of Science and Technology Austria·JournalScience Immunology·TypeExperimental study·DateSep 1, 2023